Nov 1, 2007: PerkinElmer India recently unveiled its latest generation of products as part of its expansion plan for the fast growing Indian life sciences and instrumentation market. In an interview with BioSpectrum, Gregory L Summe, Chairman & CEO, PerkinElmer, who was recently in India, highlighted the company’s India specific business plans. Excerpts:

What is the contribution of the Asia Pacific market to the global sales of PerkinElmer?
Asia Pacific makes for about 20 percent of our revenue and about 40 percent of our people are based in the Asia Pacific region. We have more of our manufacturing activities over here. The percentage of people will grow because we are investing ahead of the demand, and this region is growing faster than the rest of the world. It has a higher growth rate than Europe or the Americas so it is climbing as a percent. Within the Asia Pacific region, India has been a strong performer for us—at more than 20 percent a year.

How do you look at India as a market?
We are looking at India as a developing marketplace. India is a growing resource, a business offsite. We have been in the market for about 25 years and we continue to step up our investments. We originally started as a group of distributors and then we had a joint venture structure. We now have a wholly owned subsidiary and we have invested millions of dollars. That was from a point of view to move faster and quicker. Today, we have nine major offices in India.

What are your major businesses in India?
Today, we are looking at three major businesses in India. One is environmental and health sciences that includes air and water, food safety, quality, biofuels and pharma QA QC. The second one is our life sciences business, which is a tool of discovery. This is helping identify targets in evaluating compounds against cells, for example as in biochemical screening. The third is genetic screening and we are the world’s leading provider of testing for newborns for inborn errors of metabolism.

How successful have you been in tapping these three areas in India?
I think these are still early days. In all cases these markets are just at the beginning because the economic growth here is phenomenal and is continuously growing with an equal measure of growth in terms of analytical scientists. The pharma industry is continuing to develop and become more sophisticated. Twenty percent of the world’s babies are born in India, but there is almost no genetic screening as compared to the US where there is 100 percent screening on 29 conditions on every baby. So, we have made some early efforts with public and private people towards this end. I think, these markets will continue to grow owing to globalization and industrialization.

PerkinElmer acquired the remaining minority interest in PerkinElmer India making the Indian arm a wholly owned subsidiary. What was the strategy behind this move?
It is about speeding capability. If you have to be successful in the Indian market, you have to be an Indian company. This means knowing the country’s culture and customs so that you’re quick to respond to the customer’s needs and develop exactly what they need. Otherwise, you are just an exporter, a visitor to the market and we don’t want to be a visitor to the market. We want to be a part of the market.

Are you looking at any partnerships?
We are certainly in discussions with people to partner and develop value-end of the instrument market. And we have also got some partners on the business processing side.

The company went on a buying spree in 2006 and acquired six companies? Are you looking at any more acquisitions?
We continue to be active in the acquisition marketplace. We have a robust pipeline of deals and we will continue to do that. What we are looking for is specialty companies with high growth rate with technology that fits across our various business lines.

What are the new markets you’re looking at?
I think India, Eastern Europe and China are growing markets that we are looking at.